Latest Competition News

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Delegat Group (NZX:DGL) reported a 20% jump in operating NPAT to NZD 61.5 million for FY26, driven by record EBITDA and a 4% rise in global case sales. The Board declared a 22-cent dividend, up 10%, while net debt fell by NZD 51.8 million.

Comvita Limited has swung back to profitability in FY26, reporting $7.7 million net profit after a $40.5 million capital raise that brought Southeast Asian consumer giant F&N Ventures on board with a near 20% stake.

Vault Minerals has secured a key regulatory waiver from the ACCC for its merger with Genesis Minerals, removing a major obstacle and keeping the deal on track for shareholder approval later this year.

Austco Healthcare has delivered record FY26 financial results, driven by strong organic growth, acquisitions, and a growing software maintenance base, positioning the company for sustained earnings momentum.

NEXTDC has swung to a statutory profit of $82.1 million in FY26, driven by a record 202% jump in contracted utilisation and a strategic shift in lease accounting that added a $128.8 million fair value gain. The company’s $3.4 billion capital expenditure underscores its aggressive expansion, including the opening of its first international data centre in Kuala Lumpur.

Dubber Corporation Limited (ASX:DUB) posted a 17% revenue drop in FY26 to $35.1 million, mainly due to a major contract loss in Europe, but narrowed its net loss by 78% excluding impairments and achieved cash flow breakeven in H2.

Almasar Minerals Limited (ASX:AMK) is launching an IPO to fund early-stage exploration across five licences in Saudi Arabia’s Arabian Shield, targeting gold and copper mineralisation.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

Australian Dairy Nutritionals reported a 47% reduction in net loss for FY26, driven by a 66% revenue jump in its nutritional powders segment, which now makes up 70% of total revenue.

Transmetro Corporation lifted its net profit after tax by nearly 50% to $4.489 million for FY26, driven by a 10.4% revenue increase and a 23.4% jump in EBITDA. The hospitality operator also raised its fully franked final dividend to 6 cents per share.